New book by Larry Connors Click here Improve your trading - See how
The company's net income for third quarter ended September 30, 2009 was $192.2 million or $1.02 per share, up from $110.8 million or $0.56 per share in the year-ago quarter.
Quest Diagnostics' income from continuing operations for the quarter was $192 million or $1.02 per share compared to $160 million or $0.81 per share in the third-quarter of 2008. In 2008, third quarter results were reduced by a $0.03 per share charge associated with the write-down of an equity investment, and a $0.02 per share impact associated with hurricanes, according to the company. On average, 15 analysts polled by Thomson Reuters expected the company to earn $0.96 per share for the third-quarter of 2009.
A major chunk of the company's revenue comes from its clinical testing business, with the balance derived from insurer services, clinical trials testing, diagnostic products and healthcare information technology. Revenue for the quarter increased 3.9% to $1.89 billion from $1.82 billion in the comparable quarter last year. Clinical testing revenues increased by 4.3% in the third-quarter of 2009 compared to the prior year. The company's revenue was inline with Wall Street analysts' expectation of $1.89 billion.
The company noted that its reported testing volume for the quarter was unchanged from the prior year and reflected a 23% decline in drugs-of-abuse testing volume, which is sensitive to hiring trends, and which reduced the company's consolidated volume by 1.7%.
Quest Diagnostics' bad debt expense as a percentage of revenues for the quarter was 4.4%, unchanged from the second quarter and the prior year.
The company's cash flow from operations for the quarter improved to $374 million from $329 million in the comparable quarter a year before. During the quarter, Quest Diagnostics repurchased $100 million of its common shares and made capital expenditures of $41 million.
For the first nine months of 2009, the company's net income was $547.5 million or $2.90 per share, compared to $411.7 million or $2.09 per share in the year-ago period.
The company's income from continuing operations for the nine-month period increased to $549 million or $2.91 per share from $463 million or $2.35 per share in the comparable period a year before.
Quest Diagnostics' revenue for nine months increased 2.9% to $5.6 billion from $5.44 billion in the comparable period last year.
Surya Mohapatra, Chairman and CEO of Quest Diagnostics said, "Quest Diagnostics' strong financial performance continues to be driven by increased demand in testing for cancer, sexually transmitted diseases, allergies and Vitamin D levels."
Based on its strong performance, the company raised its full-year guidance for income from continuing operations to a range of $3.80 to $3.85 per share from its prior outlook of $3.70 - $3.80 per share. The company expects revenue growth of approximately 3% for 2009. In 2008, the company's revenue totaled $7.25 billion. Wall Street analysts have earnings estimate pegged at $3.80 per share and revenue estimate of $7.48 billion.
Given the increasing awareness about early detection and prevention of diseases and the aging of global population, Quest Diagnostics, which continues to focus on innovation and launch new commercial tests, is a stock worth watching.
DGX, which has thus far hit a 52-week low of $39.24 and 52-week high of $57.19, closed Monday's trade at $56.71. In pre-market trading Tuesday, the stock is up 3.81% at $58.87.
For comments and feedback: contact editorial@rttnews.com Copyright(c) 2009 RTTNews.com, Inc. All Rights Reserved
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
